AC Immune (ACIU) Receivables - Accured (2014 - 2026)

AC Immune (ACIU) has reported Receivables - Accured for 13 consecutive years, with $293.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Accured rose 28448.02% year-over-year to $293.7 million; the TTM figure through Mar 2026 stood at $293.7 million (up 28448.02% YoY), while the FY2025 annual figure was $434.2 million, up 34511.0% from the prior year.
• Receivables - Accured slipped to $293.7 million in Q1 2026 per ACIU's latest filing, from $450.4 million in the prior quarter.
• Across five years, Receivables - Accured topped out at $450.4 million in Q4 2025 and bottomed at $51772.8 in Q3 2022.
• Historically, Receivables - Accured has averaged $96.6 million across 5 years, with a median of $750718.5 in 2023.
• Annual changes were most pronounced in 2022 — Receivables - Accured plunged 99.96% — and 2023, when it jumped 65383.05%.
• AC Immune's Receivables - Accured stood at $423512.9 in 2022, then surged by 65383.05% to $277.3 million in 2023, then plunged by 99.55% to $1.3 million in 2024, then soared by 35803.5% to $450.4 million in 2025, then slumped by 34.79% to $293.7 million in 2026.
• Business Quant data shows ACIU's Receivables - Accured at $293.7 million in Q1 2026, $450.4 million in Q4 2025, and $502544.0 in Q3 2025.